Ahmedabad: Cadila Healthcare Ltd (Zydus Cadila) on Tuesday said it has received final approval from the USFDA for Bupropion Hydrochloride Extended-release Tablets USP (XL) in the strength of 300 mg.
The drug falls in the anti-depressant segment, according to a company release here.
The estimated sales in 2013, as per IMS, for this product was $255.9 million. The total market for Bupropion was estimated at $526.7 million.
The group now has 87 approvals and has so far filed 216 ANDAs since the start of filing process in FY 2003-04.
No comments:
Post a Comment